CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis

IntroductionSeveral trials have demonstrated that angiotensin converting enzyme inhibitors (ACEIs) decrease cardiovascular (CV) mortality rates in patients with heart failure; however, the Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) and European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) trials failed to show significant similar preventive effects in normal ejection fraction patients. We evaluated the baseline coronary artery calcium (CAC) score as a predictor of the effects of ACEIs/angiotensin receptor blockers (ARBs) on outcomes among normal ejection fraction participants. MethodologyOf 6814 MultiEthnic Study for Atherosclerosis population participants (after exclusion of the patients temporarily using ACEIs and/or ARBs during follow-up), we evaluated 2906 participants who never used ACEIs/ARBs and 368 (8.7%) participants who constantly used them during all baseline and follow-up examinations. In the population studied, 53.9% were men, aged 60.8±10.0 years, who had no apparent clinical CV disease. We compared CV event rates and multivariable-adjusted hazard ratios after stratifying by ACEI/ARB use and stratifying CAC scores by category (0, 1–399, and ≥400). ResultsThe event rates varied from 1.8 to 41.2/1000 person years among the CAC groups. Among the participants with a 1–399 CAC score, ACEI/ARB users had significantly lower event rates than nonusers (4.9 vs. 8.2, respectively). Hazard ratio in the adjusted model was 3.1 (95% confidence interval 1.14–8.78, P<0.05). There was no significant event rate difference between ACEI/ARB users and nonusers among other CAC groups. ConclusionThe use of ACEIs/ARBs was associated with significantly fewer CV events in asymptomatic participants with low to intermediate CAC scores. Thus, better risk stratification in asymptomatic individuals (such as using CAC scores) may assist in proper selection of patients for further CV risk reduction strategies.

[1]  E. Boersma,et al.  Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients , 2012, European heart journal.

[2]  Matthew J Budoff,et al.  Coronary artery and thoracic calcium on noncontrast thoracic CT scans: comparison of ungated and gated examinations in patients from the COPD Gene cohort. , 2011, Journal of cardiovascular computed tomography.

[3]  M. Budoff,et al.  Understanding the Utility of Zero Coronary Calcium as a Prognostic Test: A Bayesian Approach , 2011, Circulation. Cardiovascular quality and outcomes.

[4]  J. Guo,et al.  ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008 , 2010, Journal of managed care pharmacy : JMCP.

[5]  R. Kronmal,et al.  Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2009, American heart journal.

[6]  Hiroto Utsunomiya,et al.  Characterization of noncalcified coronary plaques and identification of culprit lesions in patients with acute coronary syndrome by 64-slice computed tomography. , 2009, JACC. Cardiovascular imaging.

[7]  Jeroen J. Bax,et al.  Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. , 2008, European heart journal.

[8]  M. Budoff,et al.  Prognostic significance of zero coronary calcium scores on cardiac computed tomography. , 2007, Journal of cardiovascular computed tomography.

[9]  Hirofumi Anno,et al.  Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. , 2007, Journal of the American College of Cardiology.

[10]  Kukin Ml.  The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.

[11]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[12]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[13]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.